{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:47:57Z","timestamp":1771667277776,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-IT-236-1320"],"award-info":[{"award-number":["IN-IT-236-1320"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s40261-019-00840-2","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T17:03:11Z","timestamp":1568739791000},"page":"1239-1249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen: Results from an Observational Cohort Study"],"prefix":"10.1007","volume":"39","author":[{"given":"Esther","family":"Merlini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico A.","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Casabianca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Magnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Ancona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Tincati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"d\u2019Arminio Monforte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-4828","authenticated-orcid":false,"given":"Giulia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,17]]},"reference":[{"issue":"Suppl 5","key":"840_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hiv.12440","volume":"17","author":"F Raffi","year":"2016","unstructured":"Raffi F, Esser S, Nunnari G, Perez-Valero I, Waters L. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens. HIV Med. 2016;17(Suppl 5):3\u201316.","journal-title":"HIV Med."},{"key":"840_CR2","unstructured":"European AIDS Clinical Society. Guidelines. Version 9.0, October 2017. 2017. \nhttp:\/\/www.eacsociety.org\/files\/guidelines_9.0-english.pdf\n\n. Accessed 9 Aug 2019."},{"key":"840_CR3","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (DHHS Antiretroviral Treatment Panel). 2018. Department of Health and Human Services \nhttps:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf\n\n. Accessed 9 Aug 2019."},{"issue":"12","key":"840_CR4","doi-asserted-by":"crossref","first-page":"e81355","DOI":"10.1371\/journal.pone.0081355","volume":"8","author":"H Samji","year":"2013","unstructured":"Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355.","journal-title":"PLoS One."},{"issue":"4","key":"840_CR5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/hiv.12421","volume":"18","author":"S Teeraananchai","year":"2017","unstructured":"Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017;18(4):256\u201366.","journal-title":"HIV Med."},{"issue":"4","key":"840_CR6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2013.10.001","volume":"39","author":"SG Deeks","year":"2013","unstructured":"Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013;39(4):633\u201345.","journal-title":"Immunity."},{"issue":"8","key":"840_CR7","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/infdis\/jiu238","volume":"210","author":"PW Hunt","year":"2014","unstructured":"Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210(8):1228\u201338.","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"840_CR8","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.thromres.2014.03.012","volume":"133","author":"Funderburg NT, Lederman MM","year":"2014","unstructured":"Funderburg NT, Lederman MM. Coagulation and morbidity in treated HIV infection. Thromb Res. 2014;133(Suppl 1):S21\u20134.","journal-title":"Thromb Res."},{"issue":"8","key":"840_CR9","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/infdis\/jir507","volume":"204","author":"MM Lederman","year":"2011","unstructured":"Lederman MM, Calabrese L, Funderburg NT, Clagett B, Medvik K, Bonilla H, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011;204(8):1217\u201326.","journal-title":"J Infect Dis."},{"issue":"3","key":"840_CR10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11904-017-0356-x","volume":"14","author":"CO Hileman","year":"2017","unstructured":"Hileman CO, Funderburg NT. Inflammation, immune activation, and antiretroviral therapy in HIV. Curr HIV\/AIDS Rep. 2017;14(3):93\u2013100.","journal-title":"Curr HIV\/AIDS Rep."},{"issue":"10","key":"840_CR11","doi-asserted-by":"crossref","first-page":"e0139474","DOI":"10.1371\/journal.pone.0139474","volume":"10","author":"MR McCausland","year":"2015","unstructured":"McCausland MR, Juchnowski SM, Zidar DA, Kuritzkes DR, Andrade A, Sieg SF, et al. Altered monocyte phenotype in HIV-1 infection tends to normalize with integrase-inhibitor-based antiretroviral therapy. PLoS One. 2015;10(10):e0139474.","journal-title":"PLoS One."},{"issue":"3","key":"840_CR12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/infdis\/jiv004","volume":"212","author":"CO Hileman","year":"2015","unstructured":"Hileman CO, Kinley B, Scharen-Guivel V, Melbourne K, Szwarcberg J, Robinson J, et al. Differential reduction in monocyte activation and vascular inflammation with integrase inhibitor-based initial antiretroviral therapy among HIV-infected individuals. J Infect Dis. 2015;212(3):345\u201354.","journal-title":"J Infect Dis."},{"issue":"4","key":"840_CR13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/cid\/civ327","volume":"61","author":"T Kelesidis","year":"2015","unstructured":"Kelesidis T, Tran TT, Stein JH, Brown TT, Moser C, Ribaudo HJ, et al. Changes in inflammation and immune activation with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy: ACTG 5260s. Clin Infect Dis. 2015;61(4):651\u201360.","journal-title":"Clin Infect Dis."},{"issue":"18","key":"840_CR14","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1097\/QAD.0b013e328359f29c","volume":"26","author":"E Martinez","year":"2012","unstructured":"Martinez E, D\u2019Albuquerque PM, Llibre JM, Gutierrez F, Podzamczer D, Antela A, SPIRAL Trial Group, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS. 2012;26(18):2315\u201326.","journal-title":"AIDS."},{"issue":"6","key":"840_CR15","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/infdis\/jit280","volume":"208","author":"EF Silva","year":"2013","unstructured":"Silva EF, Charreau I, Gourmel B, Mourah S, Kalidi I, Guillon B, ANRS 138 EASIER Study Group, et al. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy. J Infect Dis. 2013;208(6):892\u20137.","journal-title":"J Infect Dis."},{"issue":"7","key":"840_CR16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/hiv.12128","volume":"15","author":"JE Lake","year":"2014","unstructured":"Lake JE, McComsey GA, Hulgan T, Wanke CA, Mangili A, Walmsley SL, et al. Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation trial. HIV Med. 2014;15(7):431\u201341.","journal-title":"HIV Med."},{"issue":"1","key":"840_CR17","doi-asserted-by":"crossref","first-page":"21526","DOI":"10.7448\/IAS.20.1.21526","volume":"20","author":"MJ Villanueva-Mill\u00e1n","year":"2017","unstructured":"Villanueva-Mill\u00e1n MJ, P\u00e9rez-Matute P, Recio-Fern\u00e1ndez E, Lezana Rosales JM, Oteo JA. Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients. J Int AIDS Soc. 2017;20(1):21526.","journal-title":"J Int AIDS Soc."},{"key":"840_CR18","doi-asserted-by":"crossref","first-page":"569819","DOI":"10.1155\/2014\/569819","volume":"2014","author":"JJ Anzinger","year":"2014","unstructured":"Anzinger JJ, Butterfield TR, Angelovich TA, Crowe SM, Palmer CS. Monocytes as regulators of inflammation and HIV-related comorbidities during cART. J Immunol Res. 2014;2014:569819.","journal-title":"J Immunol Res."},{"issue":"12","key":"840_CR19","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1097\/QAD.0000000000001875","volume":"32","author":"P Duffau","year":"2018","unstructured":"Duffau P, Ozanne A, Bonnet F, Lazaro E, Cazanave C, Blanco P, et al. Multimorbidity, age-related comorbidities and mortality: association of activation, senescence and inflammation markers in HIV adults. AIDS. 2018;32(12):1651\u201360.","journal-title":"AIDS."},{"issue":"11","key":"840_CR20","doi-asserted-by":"crossref","first-page":"e111919","DOI":"10.1371\/journal.pone.0111919","volume":"9","author":"A Casabianca","year":"2014","unstructured":"Casabianca A, Orlandi C, Canovari B, Scotti M, Acetoso M, Valentini M, et al. A real time PCR platform for the simultaneous quantification of total and extrachromosomal HIV DNA forms in blood of HIV-1 infected patients. PLoS One. 2014;9(11):e111919.","journal-title":"PLoS One."},{"issue":"3","key":"840_CR21","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1182\/blood-2003-04-1203","volume":"103","author":"A Harari","year":"2004","unstructured":"Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood. 2004;103(3):966\u201372.","journal-title":"Blood."},{"issue":"12","key":"840_CR22","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1002\/eji.200425324","volume":"34","author":"A Harari","year":"2004","unstructured":"Harari A, Vallelian F, Pantaleo G. Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur J Immunol. 2004;34(12):3525\u201333.","journal-title":"Eur J Immunol."},{"issue":"41","key":"840_CR23","doi-asserted-by":"crossref","first-page":"16233","DOI":"10.1073\/pnas.0707570104","volume":"104","author":"A Harari","year":"2007","unstructured":"Harari A, Cellerai C, Bellutti Enders F, Kostler J, Codarri L, Tapia G, et al. Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci USA. 2007;104(41):16233\u20138.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"12","key":"840_CR24","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1182\/blood-2005-12-4818","volume":"107","author":"MR Betts","year":"2006","unstructured":"Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006;107(12):4781\u20139.","journal-title":"Blood."},{"issue":"4","key":"840_CR25","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/COH.0000000000000072","volume":"9","author":"PW Hunt","year":"2014","unstructured":"Hunt PW. HIV and aging: emerging research issues. Curr Opin HIV AIDS. 2014;9(4):302\u20138.","journal-title":"Curr Opin HIV AIDS."},{"issue":"Suppl 2","key":"840_CR26","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1093\/infdis\/jiw275","volume":"214","author":"PW Hunt","year":"2016","unstructured":"Hunt PW, Lee SA, Siedner MJ. Immunologic biomarkers, morbidity, and mortality in treated HIV infection. J Infect Dis. 2016;214(Suppl 2):S44\u201350.","journal-title":"J Infect Dis."},{"key":"840_CR27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.antiviral.2016.05.013","volume":"132","author":"R Moure","year":"2016","unstructured":"Moure R, Domingo P, Gallego-Escuredo JM, Villarroya J, Gutierrez Mdel M, Mateo MG, et al. Impact of elvitegravir on human adipocytes: alterations in differentiation, gene expression and release of adipokines and cytokines. Antivir Res. 2016;132:59\u201365.","journal-title":"Antivir Res."},{"key":"840_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1095","author":"S Moron-Lopez","year":"2018","unstructured":"Moron-Lopez S, Navarro J, Jimenez M, Rutsaert S, Urrea V, Puertas MC, et al. Switching from a protease inhibitor-based regimen to a dolutegravir-based regimen: a randomized clinical trial to determine the effect on peripheral blood and ileum biopsies from ART-suppressed HIV-infected individuals. Clin Infect Dis. 2018. \nhttps:\/\/doi.org\/10.1093\/cid\/ciy1095\n\n(Epub 2018 Dec 24).","journal-title":"Clin Infect Dis"},{"issue":"2","key":"840_CR29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/COH.0000000000000227","volume":"11","author":"CT Longenecker","year":"2016","unstructured":"Longenecker CT, Sullivan C, Baker JV. Immune activation and cardiovascular disease in chronic HIV infection. Curr Opin HIV AIDS. 2016;11(2):216\u201325.","journal-title":"Curr Opin HIV AIDS."},{"issue":"1","key":"840_CR30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3851\/IMP3091","volume":"22","author":"NT Funderburg","year":"2017","unstructured":"Funderburg NT, Xu D, Playford MP, Joshi AA, Andrade A, Kuritzkes DR, et al. Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity. Antivir Ther. 2017;22(1):71\u20135.","journal-title":"Antivir Ther."},{"issue":"6","key":"840_CR31","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiq118","volume":"203","author":"NG Sandler","year":"2011","unstructured":"Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780\u201390.","journal-title":"J Infect Dis."},{"issue":"9","key":"840_CR32","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1097\/QAD.0b013e32835f2b49","volume":"27","author":"KB Patterson","year":"2013","unstructured":"Patterson KB, Prince HA, Stevens T, Shaheen NJ, Dellon ES, Madanick RD, et al. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS. 2013;27(9):1413\u20139.","journal-title":"AIDS."},{"issue":"1","key":"840_CR33","doi-asserted-by":"crossref","first-page":"e1005381","DOI":"10.1371\/journal.ppat.1005381","volume":"12","author":"S Serrano-Villar","year":"2016","unstructured":"Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Chun TW, Mann S, et al. Effects of combined CCR33\/integrase inhibitors-based regimen on mucosal immunity in HIV-infected patients naive to antiretroviral therapy: a pilot randomized trial. PLoS Pathog. 2016;12(1):e1005381.","journal-title":"PLoS Pathog."},{"key":"840_CR34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2018.10.017","volume":"160","author":"M Surdo","year":"2018","unstructured":"Surdo M, Cortese MF, Orlandi C, Di Santo F, Aquaro S, Magnani M, et al. Different kinetics of viral replication and DNA integration in the main HIV-1 cellular reservoirs in the presence and absence of integrase inhibitors. Antivir Res. 2018;160:165\u201374.","journal-title":"Antivir Res."},{"key":"840_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12626","author":"D Sculier","year":"2018","unstructured":"Sculier D, Doco-Lecompte T, Yerly S, Metzner KJ, Decosterd LA, Calmy A. Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study. HIV Med. 2018. \nhttps:\/\/doi.org\/10.1111\/hiv.12626\n\n(Epub 2018 Jun 22).","journal-title":"HIV Med."},{"key":"840_CR36","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nm.2111","volume":"16","author":"MJ Buzon","year":"2010","unstructured":"Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010;16:460\u20135.","journal-title":"Nat Med."},{"issue":"2","key":"840_CR37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3851\/IMP1917","volume":"17","author":"JM Llibre","year":"2012","unstructured":"Llibre JM, Buzon MJ, Massanella M, Esteve A, Dahl V, Puertas MC, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther. 2012;17(2):355\u201364.","journal-title":"Antivir Ther."},{"key":"840_CR38","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/cid\/cir721","volume":"54","author":"GJ Besson","year":"2012","unstructured":"Besson GJ, McMahon D, Maldarelli F, Mellors JW. Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. Clin Infect Dis. 2012;54:451\u20133.","journal-title":"Clin Infect Dis."},{"issue":"16","key":"840_CR39","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1097\/QAD.0b013e32833ef7bb","volume":"24","author":"SA Yukl","year":"2010","unstructured":"Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010;24(16):2451\u201360.","journal-title":"AIDS."},{"issue":"6","key":"840_CR40","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1086\/650749","volume":"50","author":"D McMahon","year":"2010","unstructured":"McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010;50(6):912\u20139.","journal-title":"Clin Infect Dis."},{"issue":"9","key":"840_CR41","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/jac\/dkx166","volume":"72","author":"EC Ngo Bell","year":"2017","unstructured":"Ngo Bell EC, Vandenhende MA, Caldato S, Saunier A, Bellecave P, Tumiotto C, et al. High decay of blood HIV reservoir when tenofovir\/emtricitabine\/elvitegravir\/cobicistat is initiated during the acute primary HIV infection. J Antimicrob Chemother. 2017;72(9):2681\u20133.","journal-title":"J Antimicrob Chemother."},{"issue":"2","key":"840_CR42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00042560-200002010-00006","volume":"23","author":"M Tumbarello","year":"2000","unstructured":"Tumbarello M, Tacconelli E, Donati KG, Citton R, Leone F, Spanu T, et al. HIV-associated bacteremia: how it has changed in the highly active antiretroviral therapy (HAART) era. J Acquir Immune Defic Syndr. 2000;23(2):145\u201351.","journal-title":"J Acquir Immune Defic Syndr."},{"key":"840_CR43","doi-asserted-by":"crossref","first-page":"17344","DOI":"10.7448\/IAS.16.1.17344","volume":"16","author":"JM Silva Jr","year":"2013","unstructured":"Silva JM Jr, dos Santos Sde S. Sepsis in AIDS patients: clinical, etiological and inflammatory characteristics. J Int AIDS Soc. 2013;16:17344.","journal-title":"J Int AIDS Soc."},{"issue":"3","key":"840_CR44","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/21505594.2016.1158359","volume":"7","author":"L Taramasso","year":"2016","unstructured":"Taramasso L, Tatarelli P, Di Biagio A. Bloodstream infections in HIV-infected patients. Virulence. 2016;7(3):320\u20138.","journal-title":"Virulence."},{"issue":"4","key":"840_CR45","doi-asserted-by":"crossref","first-page":"R202","DOI":"10.1186\/cc10419","volume":"15","author":"HH Chiang","year":"2011","unstructured":"Chiang HH, Hung CC, Lee CM, Chen HY, Chen MY, Sheng WH, et al. Admissions to intensive care unit of HIV-infected patients in the era of highly active antiretroviral therapy: etiology and prognostic factors. Crit Care. 2011;15(4):R202.","journal-title":"Crit Care."},{"issue":"2","key":"840_CR46","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/COH.0000000000000230","volume":"11","author":"M Massanella","year":"2016","unstructured":"Massanella M, Fromentin R, Chomont N. Residual inflammation and viral reservoirs: alliance against an HIV cure. Curr Opin HIV AIDS. 2016;11(2):234\u201341.","journal-title":"Curr Opin HIV AIDS."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00840-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-019-00840-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00840-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T23:38:13Z","timestamp":1600213093000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-019-00840-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["840"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00840-2","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,17]]},"assertion":[{"value":"17 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was supported by Unrestricted Educational Grant no. IN-IT-236-1320 from Gilead Italia to Giulia Marchetti.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"EM., F.A.C., A.C., C.O., M.M., G.A., C.T., and A.D.M. declare that they have no conflict of interests. G.M. received Unrestricted Educational Grant no. IN-IT-236-1320 from Gilead Italia.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures in this study were in accordance with the 1964 Helsinki Declaration (and its amendments). The ethics committee of ASST Santi Paolo e Carlo specifically approved this study (protocol no. 4386 10 April 2015 and approval no. 238 2 April 2015).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All subjects gave written informed consent in accordance with the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}